These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29962407)

  • 1. Development of a Screening System for Targeting Carriers Using Peptide-Modified Liposomes and Tissue Sections.
    Negishi Y; Hamano N; Sato H; Katagiri F; Takatori K; Endo-Takahashi Y; Kikkawa Y; Nomizu M
    Biol Pharm Bull; 2018; 41(7):1107-1111. PubMed ID: 29962407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of the C16Y peptide on nanoparticles is an effective approach to target endothelial and cancer cells via the integrin receptor.
    Hamano N; Negishi Y; Fujisawa A; Manandhar M; Sato H; Katagiri F; Nomizu M; Aramaki Y
    Int J Pharm; 2012 May; 428(1-2):114-7. PubMed ID: 22421321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced active targeting via cooperative binding of ligands on liposomes to target receptors.
    Sugiyama T; Asai T; Nedachi YM; Katanasaka Y; Shimizu K; Maeda N; Oku N
    PLoS One; 2013; 8(6):e67550. PubMed ID: 23840738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
    Yamamoto S; Sakurai Y; Harashima H
    Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
    Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
    J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of Stability and Efficacy of C16Y Therapeutic Peptide via Molecular Self-Assembly into Tumor-Responsive Nanoformulation.
    Ding Y; Ji T; Zhao Y; Zhang Y; Zhao X; Zhao R; Lang J; Zhao X; Shi J; Sukumar S; Nie G
    Mol Cancer Ther; 2015 Oct; 14(10):2390-400. PubMed ID: 26269603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting.
    Chang M; Lu S; Zhang F; Zuo T; Guan Y; Wei T; Shao W; Lin G
    Colloids Surf B Biointerfaces; 2015 May; 129():175-82. PubMed ID: 25851582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
    Wang F; Chen L; Zhang R; Chen Z; Zhu L
    J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906).
    Scherzinger-Laude K; Schönherr C; Lewrick F; Süss R; Francese G; Rössler J
    Int J Nanomedicine; 2013; 8():2197-211. PubMed ID: 23818777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
    Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
    J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
    Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
    Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma.
    Shi K; Li J; Cao Z; Yang P; Qiu Y; Yang B; Wang Y; Long Y; Liu Y; Zhang Q; Qian J; Zhang Z; Gao H; He Q
    J Control Release; 2015 Nov; 217():138-50. PubMed ID: 26368312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NGR-modified pH-sensitive liposomes for controlled release and tumor target delivery of docetaxel.
    Gu Z; Chang M; Fan Y; Shi Y; Lin G
    Colloids Surf B Biointerfaces; 2017 Dec; 160():395-405. PubMed ID: 28965079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo.
    Kluza E; Jacobs I; Hectors SJ; Mayo KH; Griffioen AW; Strijkers GJ; Nicolay K
    J Control Release; 2012 Mar; 158(2):207-14. PubMed ID: 22079810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
    Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
    Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in an active and passive targeting to tumor and adipose tissues.
    Sakurai Y; Kajimoto K; Hatakeyama H; Harashima H
    Expert Opin Drug Deliv; 2015 Jan; 12(1):41-52. PubMed ID: 25376864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
    Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
    Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A photo-responsive peptide- and asparagine-glycine-arginine (NGR) peptide-mediated liposomal delivery system.
    Xie X; Yang Y; Yang Y; Zhang H; Li Y; Mei X
    Drug Deliv; 2016 Sep; 23(7):2445-2456. PubMed ID: 25693640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
    Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
    Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of chemosensitivity and inhibition of migration via targeting tumor epithelial-to-mesenchymal transition cells by ADH-1-modified liposomes.
    Guo Z; Li W; Yuan Y; Zheng K; Tang Y; Ma K; Cui C; Wang L; He B; Zhang Q
    Drug Deliv; 2018 Nov; 25(1):112-121. PubMed ID: 29260912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.